MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.54
+0.12
+1.05%
After Hours: 11.64 +0.1 +0.87% 17:48 01/22 EST
OPEN
11.34
PREV CLOSE
11.42
HIGH
11.61
LOW
11.12
VOLUME
961.45K
TURNOVER
--
52 WEEK HIGH
18.87
52 WEEK LOW
5.01
MARKET CAP
569.10M
P/E (TTM)
-3.7298
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Joint Pain Injections Market Qualitative And Quantitative Analysis 2021 - 2030 | Allergan Plc., Pfizer Inc
Jan 21, 2021 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Joint Pain Injections market...
marketresearch.biz · 2d ago
Bioadhesive Microspheres Market Overview And Geographical Forecast Till 2026 | Fortune Business Insights
Jan 21, 2021 (The Expresswire) -- Global " Bioadhesive Microspheres Market Size" 2020 report includes the market strategy, market orientation, expertise...
The Express Wire · 3d ago
H.C. Wainwright Sticks to Their Buy Rating for Flexion Therapeutics (FLXN)
H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $25.00. The company's
SmarterAnalyst · 3d ago
Flexion Therapeutics anticipates Q4 Zilretta sales of $26.3M
Flexion Therapeutics ([[FLXN]] -2.5%) has issued guidance for Q4 2020 and sees Zilretta sales of ~26.3M, slightly higher than consensus estimate of $25.7. For FY2020, expects net sales of ~$85.5M."As a result
Seekingalpha · 01/13 17:01
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
-- Full-year 2020 net sales estimated to be approximately $85.5 million
GlobeNewswire · 01/13 12:00
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
* Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 million * Full-year 2020 net sales estimated to be approximately $85.5 million * Company names Adam Muzikant,...
GlobeNewswire · 01/13 12:00
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference. The virtual fireside chat is schedule...
GlobeNewswire · 01/07 21:30
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investm...
GlobeNewswire · 01/07 21:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLXN. Analyze the recent business situations of Flexion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLXN stock price target is 20.77 with a high estimate of 35.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 53.20M
% Owned: 107.87%
Shares Outstanding: 49.32M
TypeInstitutionsShares
Increased
45
2.96M
New
29
3.84M
Decreased
42
2.09M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Independent Director
Patrick Mahaffy
President/Chief Executive Officer/Director
Michael Clayman
Chief Financial Officer
David Arkowitz
General Counsel/Secretary
Mark Levine
Other
Scott Kelley
Other
Melissa Layman
Other
Kerry Wentworth
Other
Christina Willwerth
Director
Elizabeth Kwo
Independent Director
Scott Canute
Independent Director
Samuel Colella
Independent Director
Heath Lukatch
Independent Director
Sandesh Mahatme
Independent Director
Ann Merrifield
Independent Director
C. Ann Merrifield
Independent Director
Alan Milinazzo
Independent Director
Mark Stejbach
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FLXN
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
More

Webull offers kinds of Flexion Therapeutics Inc stock information, including NASDAQ:FLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLXN stock methods without spending real money on the virtual paper trading platform.